Why ABVC BioPharma Stock Is Up Today
Why ABVC BioPharma Stock Is Up Today
ABVC BioPharma, Inc. (NASDAQ:ABVC) shares are trading higher Tuesday after the company announced it has entered into a global licensing agreement with ForSeeCon Eye Corporation for the company's ophthalmology pipeline.
ABVC BioPharma, Inc.（納斯達克股票代碼：ABVC）週二股價走高，此前該公司宣佈已與ForseeCon Eye Corporation就該公司的眼科產品線簽訂全球許可協議。
The Details:
細節：
ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products and clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC BioPharma表示，許可協議包括眼科產品線，包括醫療器械Vitargus許可的產品和臨床試驗、註冊、製造、供應和分銷權。
ABVC will receive the first licensing payment of $30 million in cash and shares within 30 days of executing the agreement. ABVC is entitled to another milestone payment of $3.5 million in cash after the first useful fundraise and royalties of 5% of net sales, up to $60 million, after the launch of the licensed product.
ABVC將在協議執行後的30天內收到第一筆3000萬美元現金和股票的許可付款。在許可產品推出後，ABVC有權再獲得350萬澳元現金的里程碑式付款，此前ABVC獲得了相當於淨銷售額5％（最高6000萬美元）的特許權使用費。
"We are thrilled to announce a new licensing deal that we believe will make our product available to more patients undergoing the tedious Vitrectomy procedure. This partnership underscores our commitment to providing patients with a better quality of life during and after the procedure," said Dr. Uttam Patil, ABVC's CEO.
“我們很高興地宣佈一項新的許可協議，我們相信這將使更多接受繁瑣的玻璃體切除術的患者可以使用我們的產品。這種夥伴關係凸顯了我們對在手術期間和手術後爲患者提供更好生活質量的承諾。” ABVC首席執行官烏塔姆·帕蒂爾博士說。
Related News: WallStreetBets Is Buzzing About Digital World Stock Ahead Of Trump Media's First Trade Under DJT Ticker
相關新聞：在特朗普媒體根據DJT股票進行首次交易之前，WallstreetBets正在熱議數字世界股票
Is ABVC A Good Stock To Buy?
ABVC 是一隻值得買入的好股票嗎？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like ABVC BioPharma's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投資者在決定股票是否值得買入時可以做出一些決定。除了可以在Benzinga的報價頁面（例如ABVC BioPharma的頁面）上找到的估值指標和價格走勢外，還有一些因素，例如公司是否每季度支付股息或購買大部分股票。
These are known as capital allocation programs. ABVC BioPharma does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
這些被稱爲資本分配計劃。ABVC BioPharma不支付股息，但顯然有幾種方法可以向股東返還價值。您可以隨時在Benzinga的股息日曆中搜索下一家即將派發股息的公司，並確定持有該公司股份可以獲得什麼樣的收益率。
For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of ARMOUR Residential REIT by the April 12. Once done, you can expect to receive a nominal payout of $0.24 on April 29.
例如，如果您希望獲得14.97％的年化回報率，則需要在4月12日之前購買ARMOUR住宅房地產投資信託基金的股份。完成後，您預計將在4月29日收到0.24美元的名義補助金。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on ABVC BioPharma will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
回購計劃顯然是不同的，而且變化很大。公司可以批准回購計劃，並在回購獲得批准的時間內酌情購買股票。瀏覽ABVC BioPharma的最新消息通常可以得出該公司最近是否批准了回購計劃。回購計劃通常作爲股價的支撐，作爲需求的支撐。
ABVC Price Action: According to Benzinga Pro, ABVC BioPharma shares are up 20% at $1.26 at the time of publication Tuesday.
ABVC價格走勢：根據Benzinga Pro的數據，ABVC BioPharma的股價在週二發佈時上漲了20％，至1.26美元。
譯文內容由第三人軟體翻譯。